Oramed Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORMP research report →
Price Chart
About the company
Oramed Pharmaceuticals Inc. , founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes.
- CEO
- Nadav Kidron
- IPO
- 2007
- Employees
- 13
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on ORMP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $179.26M
- P/E
- 1.04
- Fwd P/E
- 0.98
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.57
- EV/EBITDA
- 1.09
- Div Yield
- 5.71%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 72.96%
- ROIC
- -3.21%
Latest fiscal year · YoY change
- Revenue
- $2.00M+0.0%
- Gross Profit
- $13.00K+0.0%
- Op Income
- $-15,088,000
- Net Income
- $64.05M+436.0%
- EPS
- $1.53+418.8%
- OCF Growth
- -8.7%
- FCF Growth
- -31.4%
- 52W High
- $5.47
- 52W Low
- $2.09
- 50D MA
- $4.64
- 200D MA
- $3.94
- Beta
- 1.28
- RSI (14)
- 36
- Avg Volume
- 194.57K
No earnings-call transcripts are available for ORMP yet.
- Free Float
- 77.2%
- Shares Outstanding
- 40.93M
- Float Shares
- 31.59M
of shares held by institutions
64 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ORMP, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mercer Global Advisors Inc /Adv | 3.81M | ▲ 1.90M |
| Aquamarine Financial (Cayman) Ltd | 2.51M | ▲ 399.86K |
| Gem Investment Advisors, LLC | 2.00M | ▲ 358.73K |
| Blackrock, Inc. | 1.61M | ▲ 1.52M |
| Murchinson Ltd. | 1.29M | ▼ 25.00K |
| Bml Capital Management, LLC | 866.27K | ▼ 2.30M |
| Boothbay Fund Management, LLC | 578.64K | ▼ 22.08K |
| Geode Capital Management, LLC | 500.69K | ▲ 476.41K |
| Goldman Sachs Group Inc | 253.29K | ▲ 253.29K |
| State Street Corp | 242.10K | ▲ 242.10K |
| Rathbones Group PLC | 233.02K | 0 |
| Vanguard Portfolio Management LLC | 229.88K | ▲ 229.88K |
Held by 61 ETFs
Biggest fund positions in ORMP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Gabay Avraham | sell | 20,000 |
| Oct 1, 26 | Hexter Joshua | sell | 30,000 |
| Sep 24, 26 | KIDRON NADAV | other | 368,765 |
| Sep 24, 26 | KIDRON NADAV | other | 349,497 |
| Sep 24, 26 | KIDRON NADAV | sell | 150,000 |
| Sep 24, 26 | KIDRON NADAV | sell | 107,000 |
| Sep 24, 26 | KIDRON NADAV | sell | 97,000 |
| Sep 24, 26 | KIDRON NADAV | sell | 196,500 |
| Sep 24, 26 | KIDRON NADAV | sell | 190,000 |
| Sep 24, 26 | KIDRON NADAV | sell | 49,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ORMP coverage
Recent articles, reports, and earnings notes.
No research on ORMP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORMP report →Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB)
defenseworld.net · Oct 4
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
seekingalpha.com · Sep 11
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
gurufocus.com · Jun 25
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
prnewswire.com · Jun 25
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
prnewswire.com · Jun 17
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
seekingalpha.com · May 22
Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & Akanda (NASDAQ:AKAN)
defenseworld.net · Apr 5
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
globenewswire.com · Mar 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.